CompletedPhase 2NCT01556009

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

Studying Gorlin syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UCSF Benioff Children's Hospital Oakland
Principal Investigator: Ervin Epstein, MD
Children's Hospital Research Institute
Intervention: Vismodegib(drug)
Enrollment: 24 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2012 – 2015

Study locations (3)

Children's Hospital Oakland Research Institiute, Oakland, California, United States
Children's Hospital Research Center Oakland, Oakland, California, United States
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01556009 on ClinicalTrials.gov

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06050122
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →

← Back to all trials